Results 191 to 200 of about 30,927 (236)
Acquired mutations in patients with relapsed/refractory CLL who progressed in the ALPINE study. [PDF]
Blood AdvBrown JR +12 more
europepmc +1 more source
We are on the right track for mantle cell lymphoma. [PDF]
Br J HaematolMoioli A, Visco C.
europepmc +1 more source
Deep learning-driven drug response prediction and mechanistic insights in cancer genomics. [PDF]
Sci RepYu G, Fan Q.
europepmc +1 more source
Commentary on "real world results of ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia: a meta-analysis of clinical studies". [PDF]
BMC Pharmacol ToxicolNamdar AB, Keikha M.
europepmc +1 more source
Leveraging the Immunomodulatory Potential of Ibrutinib for Improved Outcomes of T Cell-Mediated Therapies of B Cell Malignancies: A Narrative Review. [PDF]
Target OncolMiklos DB +4 more
europepmc +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Canadian Journal of Health Technologies, 2023
CADTH recommends that ibrutinib, in combination with venetoclax, should be reimbursed by public drug plans for the treatment of adult patients with previously untreated chronic lymphocytic leukemia (CLL), including those with 17p deletion only if certain conditions are met. In combination with venetoclax, Ibrutinib should only be covered ...
openaire +1 more source
CADTH recommends that ibrutinib, in combination with venetoclax, should be reimbursed by public drug plans for the treatment of adult patients with previously untreated chronic lymphocytic leukemia (CLL), including those with 17p deletion only if certain conditions are met. In combination with venetoclax, Ibrutinib should only be covered ...
openaire +1 more source
2018
Abnormal B-cell receptor (BCR) signalling is a key mechanism of disease progression in B-cell malignancy. Bruton's tyrosine kinase (BTK) has a pivotal role in BCR signalling. Ibrutinib (PCI-32765) is a small molecule which serves as a covalent irreversible inhibitor of BTK. It is characterized by high selectivity for BTK and high potency.
Andriani, Charalambous +2 more
openaire +2 more sources
Abnormal B-cell receptor (BCR) signalling is a key mechanism of disease progression in B-cell malignancy. Bruton's tyrosine kinase (BTK) has a pivotal role in BCR signalling. Ibrutinib (PCI-32765) is a small molecule which serves as a covalent irreversible inhibitor of BTK. It is characterized by high selectivity for BTK and high potency.
Andriani, Charalambous +2 more
openaire +2 more sources